$110 Million is the total value of Ally Bridge Group (NY) LLC's 22 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARGX | New | ARGENX SEsponsored adr | $14,917,000 | – | 39,370 | +100.0% | 13.60% | – |
| MDVL | Buy | MEDAVAIL HOLDINGS INC | $9,019,000 | +218.0% | 5,894,897 | +101.8% | 8.22% | +291.1% |
| COGT | Sell | COGENT BIOSCIENCES INC | $7,733,000 | -21.2% | 857,352 | -34.5% | 7.05% | -3.1% |
| LNTH | Sell | LANTHEUS HLDGS INC | $7,593,000 | -51.8% | 115,000 | -59.6% | 6.92% | -40.8% |
| GH | GUARDANT HEALTH INC | $6,454,000 | -39.1% | 160,000 | 0.0% | 5.88% | -25.1% | |
| ISEE | IVERIC BIO INC | $6,253,000 | -42.8% | 650,000 | 0.0% | 5.70% | -29.7% | |
| GOSS | Buy | GOSSAMER BIO INC | $5,859,000 | +50.0% | 700,000 | +55.6% | 5.34% | +84.5% |
| VRDN | VIRIDIAN THERAPEUTICS INC | $5,739,000 | -37.4% | 496,012 | 0.0% | 5.23% | -23.1% | |
| FATE | FATE THERAPEUTICS INC | $4,498,000 | -36.1% | 181,500 | 0.0% | 4.10% | -21.4% | |
| CERE | CEREVEL THERAPEUTICS HLDNG I | $4,495,000 | -24.5% | 170,000 | 0.0% | 4.10% | -7.1% | |
| KDNY | New | CHINOOK THERAPEUTICS INC | $4,373,000 | – | 250,000 | +100.0% | 3.98% | – |
| NUVB | NUVATION BIO INC | $3,684,000 | -38.4% | 1,137,152 | 0.0% | 3.36% | -24.3% | |
| ISOPLEXIS CORP | $3,564,000 | -37.0% | 1,650,118 | 0.0% | 3.25% | -22.6% | ||
| SOMALOGIC INC | $3,322,000 | -43.6% | 735,000 | 0.0% | 3.03% | -30.7% | ||
| SYRS | SYROS PHARMACEUTICALS INC | $3,239,000 | -19.1% | 3,364,895 | 0.0% | 2.95% | -0.5% | |
| New | DICE THERAPEUTICS INC | $3,217,000 | – | 207,290 | +100.0% | 2.93% | – | |
| RLMD | New | RELMADA THERAPEUTICS INC | $3,038,000 | – | 160,000 | +100.0% | 2.77% | – |
| RAPID MICRO BIOSYSTEMS INC | $3,009,000 | -36.7% | 699,664 | 0.0% | 2.74% | -22.1% | ||
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $2,907,000 | -38.0% | 1,080,566 | 0.0% | 2.65% | -23.8% | |
| New | SCIENCE 37 HOLDINGS INC | $2,834,000 | – | 1,410,155 | +100.0% | 2.58% | – | |
| STOK | STOKE THERAPEUTICS INC | $2,312,000 | -37.2% | 175,000 | 0.0% | 2.11% | -22.8% | |
| JNCE | JOUNCE THERAPEUTICS INC | $1,667,000 | -55.4% | 550,000 | 0.0% | 1.52% | -45.1% | |
| VERV | Exit | VERVE THERAPEUTICS INC | $0 | – | -105,360 | -100.0% | -1.78% | – |
| Exit | SIGHT SCIENCES INC | $0 | – | -314,804 | -100.0% | -2.70% | – | |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -60,000 | -100.0% | -3.23% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -150,000 | -100.0% | -7.48% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.